Page 157 - CW E-Magazine (4-6-2024)

News from Abroad

TECHNOLOGY LICENSING
HIF Global selects Johnson Matthey’s technology

for Uruguay e-methanol plant

UK’s Johnson Matthey (JM) has
been selected by HIF Global, an eFuels
company, as the methanol licensor for
HIF Global’s Paysandú eFuels project
in Uruguay. The facility is being touted
as the largest e-methanol plant in South
America and will use electrolytic
(green) hydrogen and waste CO from
2
an ethanol plant to produce e-methanol.
E-methanol, through use of renewable
feedstocks, enables the production of
a lower carbon fuel versus traditional
methanol. HIF Global will invest $4-bn
in the facility, making it the most signifi- per year of e-methanol. The e-methanol Oni eFuels facility in Chile, where JM
cant investment in Uruguay’s history. will be utilised to support the rapidly licenses its technology and supplies
Construction of the plant is planned for growing demand from the marine mar- the catalyst. The demo plant has suc-
2025. ket, as well as a feedstock to produce cessfully operated for over 12 months,
e-gasoline (via a methanol to gasoline producing methanol that is further pro-
JM’s e-methanol eMERALD techno- process) which will facilitate the decar- cessed into gasoline. Additionally, HIF
logy has been proven as a credible bonisation of over 150,000 vehicles. Global has announced other planned
route to decarbonise methanol produc- eFuels projects to be built in the US,
tion and this technology will be deployed This collaboration builds on Tasmania, and Chile. JM is already
at the Paysandú facility, with expected the successful demonstration of the working with HIF Global to support the
production capacity of 700,000 tonnes eMERALD technology in the HIF Haru development of these projects.

CANCER TREATMENT DRUG
AstraZeneca plans $1.5-bn ADCs facility in Singapore

Pharma giant, AstraZeneca, has ment given its reputation for excellence
revealed plans to build a $1.5-bn manu- in complex manufacturing, and I am
facturing facility in Singapore to make excited for AstraZeneca to locate our
antibody drug conjugates (ADCs). $1.5-bn ADC manufacturing facility
ADCs are engineered antibodies that in the country,” AstraZeneca’s CEO
bind to tumour cells and then release Mr. Pascal Soriot said in a statement.
cell-killing chemicals.
AstraZeneca’s in-house ADC port-
The greenfield facility, which will folio includes six wholly-owned ADCs
be the drugmaker’s first end-to-end prises antibody production, synthesis of in the clinic and many more in precli-
ADC production site, will be supported chemotherapy drug and linker, conjuga- nical development.
by Singapore Economic Development tion of drug-linker to the antibody, and
Board (EDB). It will fully incorporate filling of the completed ADC substance. The company is aiming to begin de-
all steps of the manufacturing process sign and construction of the manufactur-
at a commercial scale. Manufacturing of “Singapore is one of the world’s ing facility by the end of 2024, with tar-
ADCs is a multi-step process that com- most attractive countries for invest- geted operational readiness from 2029.

Chemical Weekly June 4, 2024 157

Contents Index to Advertisers Index to Products Advertised